PE20221902A1 - Anticuerpos anti-e-selectina, composiciones y metodos de uso - Google Patents

Anticuerpos anti-e-selectina, composiciones y metodos de uso

Info

Publication number
PE20221902A1
PE20221902A1 PE2022001465A PE2022001465A PE20221902A1 PE 20221902 A1 PE20221902 A1 PE 20221902A1 PE 2022001465 A PE2022001465 A PE 2022001465A PE 2022001465 A PE2022001465 A PE 2022001465A PE 20221902 A1 PE20221902 A1 PE 20221902A1
Authority
PE
Peru
Prior art keywords
compositions
methods
amino acid
acid sequence
selectin antibodies
Prior art date
Application number
PE2022001465A
Other languages
English (en)
Inventor
James Reasoner Apgar
Sheryl Rubio Bowley
Joanne Elizabeth-Ayriss Elwell
Laura Lin
Jatin Narula
Chuenlei Parng
Debra Denene Pittman
Swapnil Rakhe
Chihyi Vincent Yu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20221902A1 publication Critical patent/PE20221902A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN ANTICUERPO AISLADO, O FRAGMENTO DE FIJACION AL ANTIGENO DE ESTE, QUE SE FIJA ESPECIFICAMENTE A E-SELECTINA HUMANA EL CUAL ESTA DEFINIDO A TRAVES DE LA SECUENCIA AMINOACIDICA DE SUS 6 CDRS (acapites a-i), SECUENCIA AMINOCIDICA DE SU REGION VARIABLE (acapites j - m) Y LA SECUENCIA AMINOACIDICA COMPLETA DE CADENA PESADA Y LIGERA.
PE2022001465A 2020-01-24 2021-01-21 Anticuerpos anti-e-selectina, composiciones y metodos de uso PE20221902A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062965688P 2020-01-24 2020-01-24
US202063104213P 2020-10-22 2020-10-22
US202063121467P 2020-12-04 2020-12-04
PCT/IB2021/050464 WO2021148983A1 (en) 2020-01-24 2021-01-21 Anti-e-selectin antibodies, compositions and methods of use

Publications (1)

Publication Number Publication Date
PE20221902A1 true PE20221902A1 (es) 2022-12-21

Family

ID=74236245

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001465A PE20221902A1 (es) 2020-01-24 2021-01-21 Anticuerpos anti-e-selectina, composiciones y metodos de uso

Country Status (14)

Country Link
US (2) US11597770B2 (es)
EP (1) EP4093508A1 (es)
JP (1) JP7449390B2 (es)
KR (1) KR20220131293A (es)
CN (1) CN115190814A (es)
AU (1) AU2021210669A1 (es)
BR (1) BR112022014417A2 (es)
CA (1) CA3168704A1 (es)
CO (1) CO2022010244A2 (es)
IL (1) IL294921A (es)
MX (1) MX2022009130A (es)
PE (1) PE20221902A1 (es)
TW (1) TW202140558A (es)
WO (1) WO2021148983A1 (es)

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
EP0534944B1 (en) 1988-11-14 1996-09-11 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0640129A1 (en) 1990-11-23 1995-03-01 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
WO1992012729A1 (en) 1991-01-24 1992-08-06 Cytel Corporation Monoclonal antibodies to elam-1 and their uses
EP0505749A3 (en) 1991-02-26 1993-06-23 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to activated endothelial cells and their therapeutic and diagnostic use
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
DE69227618T2 (de) 1991-07-31 1999-05-06 Baylor College Medicine Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
ATE261493T1 (de) 1992-05-22 2004-03-15 Univ Montana State Antikörper mit spezifikäten gegen mehrere adhäsionsmoleküle
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
JPH09512705A (ja) 1994-03-29 1997-12-22 セルテック セラピューティクス リミテッド Ｅ−セレクチンに対する抗体
AU748561B2 (en) 1994-06-07 2002-06-06 Regents Of The University Of Minnesota Methods for inhibiting antigen specific T cell responses
JPH10501815A (ja) 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996040942A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Humanized antibodies to e-selectin
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US8119395B1 (en) 1998-02-27 2012-02-21 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000002584A2 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU782952C (en) 1999-08-25 2006-09-07 Altarex Medical Corp. Therapeutic immune condition compositions and methods
DE10056136A1 (de) 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
IL165250A0 (en) 2002-05-16 2005-12-18 Absorber Ab Methods of donor specific crossmatching
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2008508293A (ja) 2004-07-29 2008-03-21 リゴサイト ファーマスーティカルズ，インコーポレイテッド 抗セレクチン剤を用いる感染の治療および予防のための方法
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US7998740B2 (en) 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CN101679966B (zh) 2007-01-24 2014-03-12 协和发酵麒麟株式会社 具有增强的效应子活性的遗传重组抗体组合物
EP2356224A4 (en) 2008-11-10 2012-12-26 Sinai School Medicine METHOD OF INHIBITING WEB TREATMENT IN CONNECTION WITH INFLAMMATION THROUGH NEUTROPHILACTIVITY INHIBITION
US20150010563A1 (en) 2012-02-21 2015-01-08 Massachusetts Eye & Ear Infirmary Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
AU2013328881B2 (en) * 2012-10-12 2018-03-15 Arizona Board Of Regents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
DK2941302T3 (en) * 2013-01-02 2018-10-08 Glenmark Pharmaceuticals Sa ANTIBODIES BINDING TO TL1A AND THEIR USES
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20160331775A1 (en) 2015-05-14 2016-11-17 The Regents Of The University Of Michigan E-selectin inhibition works in combination with low-molecular weight heparin to decrease venous thrombosis and bleeding risk
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11014908B2 (en) 2018-11-29 2021-05-25 Pfizer Inc. Chemical compounds
CN112868090A (zh) 2019-09-12 2021-05-28 铠侠股份有限公司 基板处理装置

Also Published As

Publication number Publication date
US20210246213A1 (en) 2021-08-12
CA3168704A1 (en) 2021-07-29
MX2022009130A (es) 2022-08-22
KR20220131293A (ko) 2022-09-27
JP7449390B2 (ja) 2024-03-13
US20240076386A1 (en) 2024-03-07
IL294921A (en) 2022-09-01
EP4093508A1 (en) 2022-11-30
CN115190814A (zh) 2022-10-14
AU2021210669A1 (en) 2022-08-18
CO2022010244A2 (es) 2022-08-09
WO2021148983A1 (en) 2021-07-29
BR112022014417A2 (pt) 2022-09-13
JP2023503714A (ja) 2023-01-31
US11597770B2 (en) 2023-03-07
TW202140558A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
PE20211491A1 (es) PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
CU24648B1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
PE20221282A1 (es) Anticuerpos que se unen a hla-a2/mage-a4
CO2018011663A2 (es) Nticuerpos anti-basigin humanizados y uso de los mismos
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
PE20231504A1 (es) Anticuerpos especificos para kras y sus usos
ECSP22055004A (es) Anticuerpos anti?mertk y m?todos de uso de los mismos
PE20230374A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
PE20220708A1 (es) Anticuerpos anti-cd73
ES2684173T3 (es) Anticuerpos anti-XCR1 humano
BR112018011270A2 (pt) anticorpo isolado, composição farmacêutica, e, métodos para tratamento ou redução da taxa de recorrência de um câncer em um paciente e para detecção de células tronco do câncer.
MX2020013606A (es) Constructos de anticuerpos multiespecificos.
PE20221902A1 (es) Anticuerpos anti-e-selectina, composiciones y metodos de uso
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos